At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 78 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at how a medicine called epcoritamab works in real-world care for adults with two types of blood cancer: diffuse large B-cell lymphoma and follicular lymphoma. It is run by AbbVie. People in this study have already had two or more earlier courses of treatment.
Who can take part
- Adults due to be treated with epcoritamab after two or more earlier courses of treatment for diffuse large B-cell lymphoma or follicular lymphoma.
- Epcoritamab must be given as set out in the approved medicine information for the country taking part.
- The doctor must have already decided to treat the person with epcoritamab before they were asked to join the study.
Who may not be able to
- Any condition listed as a reason not to take epcoritamab in the approved medicine information for that country.
- Taking part at the same time in another clinical trial that tests a treatment (surveys, registries and observational studies are allowed).
What taking part involves
- • Not stated — ask the trial team.
Time commitment: Not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 700
- Started
- 2025-03-28
- Last checked
- 2026-02
Plain English Summary
What is this study?
- • Testing a new treatment for diffuse large b-cell lymphoma
- • Clinical study - 700 participants
- • Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with diffuse large b-cell lymphoma
Where?
- • Milton Keynes - Milton Keynes Hospital /ID# 272817
- • Truro - Royal Cornwall Hospital /ID# 272747
- • Cheltenham - Cheltenham General Hospital /ID# 272746
- • Portsmouth - Queen Alexandra Hospital /ID# 272744
- • +4 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL. Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally. Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Participants who are scheduled to be treated with epcoritamab for Treatment after two or more previous treatments...
- ✓Treatment with epcoritamab should be administered in accordance with the approved local label in the participating...
- ✓The decision to treat the participant should have been made by the clinician prior to, and independently of any...
Who cannot take part
- ✗Any condition included in the contraindications section of the approved local epcoritamab label in the participating...
- ✗Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study,...
See the full criteria
Where Is This Study? (8 UK sites)
Milton Keynes Hospital /ID# 272817
Milton Keynes MK6 5LD, United Kingdom
Royal Cornwall Hospital /ID# 272747
Truro TR1 3LQ, United Kingdom
Cheltenham General Hospital /ID# 272746
Cheltenham GL53 7AN, United Kingdom
Queen Alexandra Hospital /ID# 272744
Portsmouth PO6 3LY, United Kingdom
NHS Lanarkshire /ID# 276471
Airdrie ML6 0JS, United Kingdom
Nottingham City Hospital /ID# 272753
Nottingham NG5 1PB, United Kingdom
The Christie /ID# 272745
Manchester M20 4BX, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 272748
Newcastle upon Tyne NE3 3HD, United Kingdom
How to Get in Touch
Rebekah Taylor
Sponsor contactCONTACT